Advertisement
Screener

Traws Pharma, Inc. (TRAW) Operating Cash Flow

2.8 / 5 stars · 68/120 Roast Me

Traws Pharma, Inc. Operating Cash Flow

Traws Pharma, Inc. (TRAW) reported Operating Cash Flow of -$10.08 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.

Financial Statements › Cash Flow › Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-14

  • Traws Pharma, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$7.50M.
  • Traws Pharma, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$2.58M.
  • Traws Pharma, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$2.76M.
  • Traws Pharma, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$4.01M.
  • Traws Pharma, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$18.18M.
  • Traws Pharma, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$29.79M.
  • Traws Pharma, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$17.93M.
  • Traws Pharma, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$16.29M.
Period endNet Cash Provided by (Used in) Operating Activities 3 monthNet Cash Provided by (Used in) Operating Activities 6 monthNet Cash Provided by (Used in) Operating Activities 9 monthNet Cash Provided by (Used in) Operating Activities 12 month
2026-06-30-$7.50M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14
-$10.08M
10-Q · filed 2026-08-14
-$12.84M
derived: sum of 3 quarters · filed 2026-08-14
-$16.85M
derived: sum of 4 quarters · filed 2026-08-14
2026-03-31-$2.58M
10-Q · filed 2026-05-15
-$5.33M
derived: sum of 2 quarters · filed 2026-05-15
-$9.35M
derived: sum of 3 quarters · filed 2026-05-15
-$15.32M
derived: sum of 4 quarters · filed 2026-08-14
2025-12-31-$2.76M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15
-$6.77M
derived: sum of 2 quarters · filed 2026-04-15
-$12.75M
derived: sum of 3 quarters · filed 2026-08-14
-$18.18M
10-K · filed 2026-04-15
2025-09-30-$4.01M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13
-$9.99M
derived: sum of 2 quarters · filed 2026-08-14
-$15.43M
10-Q · filed 2025-11-13
-$19.47M
derived: sum of 4 quarters · filed 2026-08-14
2025-06-30-$5.98M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14
-$11.42M
10-Q · filed 2026-08-14
-$15.46M
derived: sum of 3 quarters · filed 2026-08-14
-$26.93M
derived: sum of 4 quarters · filed 2026-08-14
2025-03-31-$5.44M
10-Q · filed 2026-05-15
-$9.48M
derived: sum of 2 quarters · filed 2026-05-15
-$20.95M
derived: sum of 3 quarters · filed 2026-05-15
-$30.80M
derived: sum of 4 quarters · filed 2026-05-15
2024-12-31-$4.04M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15
-$15.52M
derived: sum of 2 quarters · filed 2026-04-15
-$25.37M
derived: sum of 3 quarters · filed 2026-04-15
-$29.79M
10-K · filed 2026-04-15
2024-09-30-$11.48M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13
-$21.33M
derived: sum of 2 quarters · filed 2025-11-13
-$25.75M
10-Q · filed 2025-11-13
-$30.18M
derived: sum of 4 quarters · filed 2025-11-13
2024-06-30-$9.85M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14
-$14.28M
10-Q · filed 2025-08-14
-$18.71M
derived: sum of 3 quarters · filed 2025-08-14
-$23.18M
derived: sum of 4 quarters · filed 2025-08-14
2024-03-31-$4.42M
10-Q · filed 2025-05-15
-$8.85M
derived: sum of 2 quarters · filed 2025-05-15
-$13.32M
derived: sum of 3 quarters · filed 2025-05-15
-$17.81M
derived: sum of 4 quarters · filed 2025-05-15
2023-12-31-$4.43M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31
-$8.90M
derived: sum of 2 quarters · filed 2025-03-31
-$13.39M
derived: sum of 3 quarters · filed 2025-03-31
-$17.93M
10-K · filed 2025-03-31
2023-09-30-$4.47M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14
-$8.96M
derived: sum of 2 quarters · filed 2024-11-14
-$13.50M
10-Q · filed 2024-11-14
-$17.39M
derived: sum of 4 quarters · filed 2024-11-14
2023-06-30-$4.49M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-15
-$9.03M
10-Q · filed 2024-08-15
-$12.92M
derived: sum of 3 quarters · filed 2024-08-15
-$16.82M
derived: sum of 4 quarters · filed 2024-08-15
2023-03-31-$4.54M
10-Q · filed 2024-05-15
-$8.43M
derived: sum of 2 quarters · filed 2024-05-15
-$12.33M
derived: sum of 3 quarters · filed 2024-05-15
-$16.54M
derived: sum of 4 quarters · filed 2024-05-15
2022-12-31-$3.88M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01
-$7.78M
derived: sum of 2 quarters · filed 2024-04-01
-$12.00M
derived: sum of 3 quarters · filed 2024-04-01
-$16.29M
10-K · filed 2024-04-01
2022-09-30-$3.90M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14
-$8.11M
derived: sum of 2 quarters · filed 2023-11-14
-$12.41M
10-Q · filed 2023-11-14
-$16.68M
derived: sum of 4 quarters · filed 2023-11-14
2022-06-30-$4.21M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14
-$8.51M
10-Q · filed 2023-08-14
-$12.78M
derived: sum of 3 quarters · filed 2023-08-14
-$17.04M
derived: sum of 4 quarters · filed 2023-08-14
2022-03-31-$4.30M
10-Q · filed 2023-05-15
-$8.56M
derived: sum of 2 quarters · filed 2023-05-15
-$12.83M
derived: sum of 3 quarters · filed 2023-05-15
-$17.14M
derived: sum of 4 quarters · filed 2023-05-15
2021-12-31-$4.26M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30
-$8.53M
derived: sum of 2 quarters · filed 2023-03-30
-$12.84M
derived: sum of 3 quarters · filed 2023-03-30
-$19.49M
10-K · filed 2023-03-30
2021-09-30-$4.27M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14
-$8.57M
derived: sum of 2 quarters · filed 2022-11-14
-$15.22M
10-Q · filed 2022-11-14
-$20.69M
derived: sum of 4 quarters · filed 2022-11-14
2021-06-30-$4.31M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15
-$10.96M
10-Q · filed 2022-08-15
-$16.42M
derived: sum of 3 quarters · filed 2022-08-15
-$22.19M
derived: sum of 4 quarters · filed 2022-08-15
2021-03-31-$6.65M
10-Q · filed 2022-05-13
-$12.12M
derived: sum of 2 quarters · filed 2022-05-13
-$17.88M
derived: sum of 3 quarters · filed 2022-05-13
-$23.26M
derived: sum of 4 quarters · filed 2022-05-13
2020-12-31-$5.47M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21
-$11.23M
derived: sum of 2 quarters · filed 2022-03-21
-$16.61M
derived: sum of 3 quarters · filed 2022-03-21
-$23.07M
10-K · filed 2022-03-21
2020-09-30-$5.76M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15
-$11.14M
derived: sum of 2 quarters · filed 2021-11-15
-$17.61M
10-Q · filed 2021-11-15
-$22.97M
derived: sum of 4 quarters · filed 2021-11-15
2020-06-30-$5.38M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16
-$11.84M
10-Q · filed 2021-08-16
-$17.20M
derived: sum of 3 quarters · filed 2021-08-16
-$21.16M
derived: sum of 4 quarters · filed 2021-08-16
2020-03-31-$6.46M
10-Q · filed 2021-05-17
-$11.82M
derived: sum of 2 quarters · filed 2021-05-17
-$15.78M
derived: sum of 3 quarters · filed 2021-05-17
-$20.69M
derived: sum of 4 quarters · filed 2021-05-17
2019-12-31-$5.36M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18
-$9.32M
derived: sum of 2 quarters · filed 2021-03-18
-$14.23M
derived: sum of 3 quarters · filed 2021-03-18
-$20.83M
10-K · filed 2021-03-18
2019-09-30-$3.96M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16
-$8.87M
derived: sum of 2 quarters · filed 2020-11-16
-$15.47M
10-Q · filed 2020-11-16
-$20.88M
derived: sum of 4 quarters · filed 2020-11-16
2019-06-30-$4.91M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12
-$11.51M
10-Q · filed 2020-08-12
-$16.92M
derived: sum of 3 quarters · filed 2020-08-12
-$24.07M
derived: sum of 4 quarters · filed 2020-08-12
2019-03-31-$6.60M
10-Q · filed 2020-05-15
-$12.01M
derived: sum of 2 quarters · filed 2020-05-15
-$19.16M
derived: sum of 3 quarters · filed 2020-05-15
-$23.79M
derived: sum of 4 quarters · filed 2020-05-15
2018-12-31-$5.41M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27
-$12.56M
derived: sum of 2 quarters · filed 2020-03-27
-$17.19M
derived: sum of 3 quarters · filed 2020-03-27
-$22.70M
10-K · filed 2020-03-27
2018-09-30-$7.15M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12
-$11.78M
derived: sum of 2 quarters · filed 2019-11-12
-$17.29M
10-Q · filed 2019-11-12
-$21.96M
derived: sum of 4 quarters · filed 2019-11-12
2018-06-30-$4.62M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14
-$10.13M
10-Q · filed 2019-08-14
-$14.81M
derived: sum of 3 quarters · filed 2019-08-14
-$22.20M
derived: sum of 4 quarters · filed 2019-08-14
2018-03-31-$5.51M
10-Q · filed 2019-05-15
-$10.18M
derived: sum of 2 quarters · filed 2019-05-15
-$17.58M
derived: sum of 3 quarters · filed 2019-05-15
-$23.27M
derived: sum of 4 quarters · filed 2019-05-15
2017-12-31-$4.67M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01
-$12.07M
derived: sum of 2 quarters · filed 2019-04-01
-$17.76M
derived: sum of 3 quarters · filed 2019-04-01
-$23.82M
10-K · filed 2019-04-01
2017-09-30-$7.40M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14
-$13.09M
derived: sum of 2 quarters · filed 2018-11-14
-$19.15M
10-Q · filed 2018-11-14
-$23.51M
derived: sum of 4 quarters · filed 2018-11-14
2017-06-30-$5.69M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14
-$11.75M
10-Q · filed 2018-08-14
-$16.11M
derived: sum of 3 quarters · filed 2018-08-14
-$18.97M
derived: sum of 4 quarters · filed 2018-08-14
2017-03-31-$6.06M
10-Q · filed 2018-05-15
-$10.42M
derived: sum of 2 quarters · filed 2018-05-15
-$13.28M
derived: sum of 3 quarters · filed 2018-05-15
2016-12-31-$4.36M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16
-$7.22M
derived: sum of 2 quarters · filed 2018-03-16
-$15.81M
10-K · filed 2018-03-16
2016-09-30-$2.86M
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09
-$11.45M
10-Q · filed 2017-11-09
2016-06-30-$8.59M
10-Q · filed 2017-08-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
Alzamend Neuro, Inc. (ALZN)United States$0.009B
Imunon, Inc. (IMNN)United States$0.008B-0.56
SOLIGENIX, INC. (SNGX)United States$0.008B
FibroBiologics, Inc. (FBLG)United States$0.009B-0.27
EXICURE, INC. (XCUR)United States$0.008B-1.54
Ensysce Biosciences, Inc. (ENSC)United States$0.008B-0.37
InMed Pharmaceuticals Inc. (INM)$0.008B-0.65
Aprea Therapeutics, Inc. (APRE)United States$0.010B-0.78
Apimeds Pharmaceuticals US, Inc. (APUS)United States$0.008B
CNS Pharmaceuticals, Inc. (CNSP)United States$0.007B